Great Point Partners’s DexCom DXCM Stock Holding History

Great Point Partners’s Portfolio DXCM Stock Details DXCM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-104,400	Closed	-$5.71M	–	41
2019 Q4	$5.71M	Sell	104,400 -500,656	-83%	-$23.7M	0.5%	29
2019 Q3	$22.6M	Buy	+605,056	New	+$23.5M	2.07%	17

Other funds holding DXCM

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Brown Advisory Baltimore, Maryland $60.9B AUM 15.24% 1-Year Est. Return

Great Point Partners's DXCM Position: Q1 2020 in Review

Great Point Partners sold out of DexCom (DXCM) in Q1 2020, closing a stake of 104,400 shares — an estimated $5.71M sold.

Great Point Partners first reported a position in DXCM in Q3 2019 and held it in 2 quarters. The position peaked at $22.6M in Q3 2019. 594 funds tracked by Wall St. Rank hold DXCM as of Q1 2020.

Great Point Partners reported no remaining DexCom position as of Q1 2020 after selling out during the quarter.
Great Point Partners sold 104,400 DexCom shares in Q1 2020, an estimated $5.71M.
Great Point Partners first reported a position in DexCom in Q3 2019 and held it in 2 quarters.
Great Point Partners's DexCom position peaked at $22.6M in Q3 2019.
594 funds tracked by Wall St. Rank held DexCom as of Q1 2020.

Based on Great Point Partners's 13F filing for Q1 2020, filed 15 May 2020.